Redefining the implications of nasogastric tube placement following radical cystectomy in the alvimopan era

Vignesh T. Packiam, Vijay A. Agrawal, Joseph J Pariser, Andrew J. Cohen, Charles U. Nottingham, Shane M. Pearce, Norm D. Smith, Gary D. Steinberg

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: Alvimopan has decreased ileus and need for nasogastric tube (NGT) after radical cystectomy (RC). However, the natural history of ileus versus intestinal obstruction in patients receiving alvimopan is not well defined. We sought to examine the implications of NGT placement before and after the introduction of alvimopan for RC patients. Methods: Retrospective review identified 278 and 293 consecutive patients who underwent RC before and after instituting alvimopan between June 2009 and May 2014. Baseline characteristics and postoperative outcomes were compared by alvimopan status. Multivariate logistic regression was performed to assess the impact of alvimopan on rates of NGT placement and reoperation for bowel complications. Results: The cohorts had similar age, stage, approach, and BMI. Patients receiving alvimopan had decreased ileus (16 vs 32 %, p < 0.01) but similar rates of reoperation for bowel complications (2.8 vs 2.7 %). On multivariate analysis, alvimopan was associated with lower risk of NGT placement (OR 0.30, p < 0.01). For patients requiring NGT placement, there was an increased rate of reoperation among patients receiving alvimopan compared with those who did not (28 vs 11 %, p = 0.03). Patients receiving alvimopan who needed NGT had significantly increased median length of stay (22 vs 7 days), need for TPN (66 vs 5.3 %), and readmission for ileus (10.3 vs 2.3 %) compared with those who did not require NGT. Conclusions: Alvimopan significantly reduced the incidence of ileus and NGT placement following RC. NGT placement was associated with an increased need for reoperation for bowel complications in the setting of alvimopan.

Original languageEnglish (US)
Pages (from-to)625-631
Number of pages7
JournalWorld Journal of Urology
Volume35
Issue number4
DOIs
StatePublished - Apr 1 2017
Externally publishedYes

Fingerprint

alvimopan
Cystectomy
Ileus
Reoperation

Keywords

  • Alvimopan
  • Cystectomy
  • Intestinal obstruction
  • Reoperation
  • Urinary bladder neoplasms

Cite this

Packiam, V. T., Agrawal, V. A., Pariser, J. J., Cohen, A. J., Nottingham, C. U., Pearce, S. M., ... Steinberg, G. D. (2017). Redefining the implications of nasogastric tube placement following radical cystectomy in the alvimopan era. World Journal of Urology, 35(4), 625-631. https://doi.org/10.1007/s00345-016-1910-7

Redefining the implications of nasogastric tube placement following radical cystectomy in the alvimopan era. / Packiam, Vignesh T.; Agrawal, Vijay A.; Pariser, Joseph J; Cohen, Andrew J.; Nottingham, Charles U.; Pearce, Shane M.; Smith, Norm D.; Steinberg, Gary D.

In: World Journal of Urology, Vol. 35, No. 4, 01.04.2017, p. 625-631.

Research output: Contribution to journalArticle

Packiam, VT, Agrawal, VA, Pariser, JJ, Cohen, AJ, Nottingham, CU, Pearce, SM, Smith, ND & Steinberg, GD 2017, 'Redefining the implications of nasogastric tube placement following radical cystectomy in the alvimopan era', World Journal of Urology, vol. 35, no. 4, pp. 625-631. https://doi.org/10.1007/s00345-016-1910-7
Packiam, Vignesh T. ; Agrawal, Vijay A. ; Pariser, Joseph J ; Cohen, Andrew J. ; Nottingham, Charles U. ; Pearce, Shane M. ; Smith, Norm D. ; Steinberg, Gary D. / Redefining the implications of nasogastric tube placement following radical cystectomy in the alvimopan era. In: World Journal of Urology. 2017 ; Vol. 35, No. 4. pp. 625-631.
@article{c1748d5290f04962845df3b49dd9a3df,
title = "Redefining the implications of nasogastric tube placement following radical cystectomy in the alvimopan era",
abstract = "Purpose: Alvimopan has decreased ileus and need for nasogastric tube (NGT) after radical cystectomy (RC). However, the natural history of ileus versus intestinal obstruction in patients receiving alvimopan is not well defined. We sought to examine the implications of NGT placement before and after the introduction of alvimopan for RC patients. Methods: Retrospective review identified 278 and 293 consecutive patients who underwent RC before and after instituting alvimopan between June 2009 and May 2014. Baseline characteristics and postoperative outcomes were compared by alvimopan status. Multivariate logistic regression was performed to assess the impact of alvimopan on rates of NGT placement and reoperation for bowel complications. Results: The cohorts had similar age, stage, approach, and BMI. Patients receiving alvimopan had decreased ileus (16 vs 32 {\%}, p < 0.01) but similar rates of reoperation for bowel complications (2.8 vs 2.7 {\%}). On multivariate analysis, alvimopan was associated with lower risk of NGT placement (OR 0.30, p < 0.01). For patients requiring NGT placement, there was an increased rate of reoperation among patients receiving alvimopan compared with those who did not (28 vs 11 {\%}, p = 0.03). Patients receiving alvimopan who needed NGT had significantly increased median length of stay (22 vs 7 days), need for TPN (66 vs 5.3 {\%}), and readmission for ileus (10.3 vs 2.3 {\%}) compared with those who did not require NGT. Conclusions: Alvimopan significantly reduced the incidence of ileus and NGT placement following RC. NGT placement was associated with an increased need for reoperation for bowel complications in the setting of alvimopan.",
keywords = "Alvimopan, Cystectomy, Intestinal obstruction, Reoperation, Urinary bladder neoplasms",
author = "Packiam, {Vignesh T.} and Agrawal, {Vijay A.} and Pariser, {Joseph J} and Cohen, {Andrew J.} and Nottingham, {Charles U.} and Pearce, {Shane M.} and Smith, {Norm D.} and Steinberg, {Gary D.}",
year = "2017",
month = "4",
day = "1",
doi = "10.1007/s00345-016-1910-7",
language = "English (US)",
volume = "35",
pages = "625--631",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Redefining the implications of nasogastric tube placement following radical cystectomy in the alvimopan era

AU - Packiam, Vignesh T.

AU - Agrawal, Vijay A.

AU - Pariser, Joseph J

AU - Cohen, Andrew J.

AU - Nottingham, Charles U.

AU - Pearce, Shane M.

AU - Smith, Norm D.

AU - Steinberg, Gary D.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Purpose: Alvimopan has decreased ileus and need for nasogastric tube (NGT) after radical cystectomy (RC). However, the natural history of ileus versus intestinal obstruction in patients receiving alvimopan is not well defined. We sought to examine the implications of NGT placement before and after the introduction of alvimopan for RC patients. Methods: Retrospective review identified 278 and 293 consecutive patients who underwent RC before and after instituting alvimopan between June 2009 and May 2014. Baseline characteristics and postoperative outcomes were compared by alvimopan status. Multivariate logistic regression was performed to assess the impact of alvimopan on rates of NGT placement and reoperation for bowel complications. Results: The cohorts had similar age, stage, approach, and BMI. Patients receiving alvimopan had decreased ileus (16 vs 32 %, p < 0.01) but similar rates of reoperation for bowel complications (2.8 vs 2.7 %). On multivariate analysis, alvimopan was associated with lower risk of NGT placement (OR 0.30, p < 0.01). For patients requiring NGT placement, there was an increased rate of reoperation among patients receiving alvimopan compared with those who did not (28 vs 11 %, p = 0.03). Patients receiving alvimopan who needed NGT had significantly increased median length of stay (22 vs 7 days), need for TPN (66 vs 5.3 %), and readmission for ileus (10.3 vs 2.3 %) compared with those who did not require NGT. Conclusions: Alvimopan significantly reduced the incidence of ileus and NGT placement following RC. NGT placement was associated with an increased need for reoperation for bowel complications in the setting of alvimopan.

AB - Purpose: Alvimopan has decreased ileus and need for nasogastric tube (NGT) after radical cystectomy (RC). However, the natural history of ileus versus intestinal obstruction in patients receiving alvimopan is not well defined. We sought to examine the implications of NGT placement before and after the introduction of alvimopan for RC patients. Methods: Retrospective review identified 278 and 293 consecutive patients who underwent RC before and after instituting alvimopan between June 2009 and May 2014. Baseline characteristics and postoperative outcomes were compared by alvimopan status. Multivariate logistic regression was performed to assess the impact of alvimopan on rates of NGT placement and reoperation for bowel complications. Results: The cohorts had similar age, stage, approach, and BMI. Patients receiving alvimopan had decreased ileus (16 vs 32 %, p < 0.01) but similar rates of reoperation for bowel complications (2.8 vs 2.7 %). On multivariate analysis, alvimopan was associated with lower risk of NGT placement (OR 0.30, p < 0.01). For patients requiring NGT placement, there was an increased rate of reoperation among patients receiving alvimopan compared with those who did not (28 vs 11 %, p = 0.03). Patients receiving alvimopan who needed NGT had significantly increased median length of stay (22 vs 7 days), need for TPN (66 vs 5.3 %), and readmission for ileus (10.3 vs 2.3 %) compared with those who did not require NGT. Conclusions: Alvimopan significantly reduced the incidence of ileus and NGT placement following RC. NGT placement was associated with an increased need for reoperation for bowel complications in the setting of alvimopan.

KW - Alvimopan

KW - Cystectomy

KW - Intestinal obstruction

KW - Reoperation

KW - Urinary bladder neoplasms

UR - http://www.scopus.com/inward/record.url?scp=84980002410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84980002410&partnerID=8YFLogxK

U2 - 10.1007/s00345-016-1910-7

DO - 10.1007/s00345-016-1910-7

M3 - Article

C2 - 27476163

AN - SCOPUS:84980002410

VL - 35

SP - 625

EP - 631

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 4

ER -